How Much Does Saxenda Cost in New Jersey in 2026?

Saxenda's Retail Price in New Jersey

The cash price for Saxenda at New Jersey retail pharmacies sits at approximately $1,349 per month in 2026, matching the Novo Nordisk list price. This buys one carton of five pre-filled 3 mL pens, each containing 18 mg of liraglutide. At the maintenance dose of 3 mg daily, one carton lasts 30 days.

Prices at individual NJ pharmacies may fluctuate slightly. Large chain pharmacies (CVS, Walgreens, Rite Aid) in the state typically price close to or at the manufacturer list. Independent pharmacies sometimes offer modest discounts, though rarely more than 3 to 5 percent off list. Costco and Sam's Club pharmacy locations in New Jersey do not require membership for prescription purchases and have historically priced GLP-1 medications slightly below major chains.

The $1,349 figure represents the pre-discount sticker price. Most patients paying out of pocket will want to layer at least one discount mechanism on top. According to the FDA-approved prescribing information for Saxenda, the recommended dose escalation starts at 0.6 mg daily for one week, increasing by 0.6 mg per week until reaching 3 mg [1]. During the first month of titration, patients use less medication, which means one carton may stretch beyond 30 days depending on how a pharmacy dispenses the initial supply.

New Jersey Medicaid Coverage for Saxenda

New Jersey Medicaid covers Saxenda with prior authorization. This means a prescriber must submit clinical documentation showing the patient meets specific criteria before NJ Medicaid will approve the claim. Standard requirements include a BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), documented failure of lifestyle intervention, and confirmation that the prescribing clinician will monitor the patient's response.

The prior authorization process in New Jersey typically takes 24 to 72 hours for an initial decision. Some Medicaid managed care organizations (MCOs) operating in the state, including Amerigroup, Horizon NJ Health, UnitedHealthcare Community Plan, and WellCare, may apply their own formulary preferences. A patient enrolled in one MCO might face a step therapy requirement (trying metformin or phentermine first), while another MCO might approve Saxenda as a first-line agent.

If Medicaid approves the prior authorization, the patient's cost share depends on their plan tier. Most NJ Medicaid beneficiaries pay $0 to $3 per prescription. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced 8.0% mean body weight loss versus 2.6% with placebo over 56 weeks, with 63.2% of liraglutide-treated patients losing at least 5% of body weight compared to 27.1% on placebo [2]. These outcomes data form the clinical backbone supporting payer coverage decisions across New Jersey.

Dr. Caroline Apovian, a former professor of medicine at Harvard Medical School and co-author of the Endocrine Society's clinical practice guidelines on obesity pharmacotherapy, stated: "Anti-obesity medications like liraglutide are not cosmetic treatments. They address the biological drivers of weight regain that lifestyle changes alone cannot overcome in many patients" [3].

Commercial Insurance Coverage in New Jersey

Commercial insurers in New Jersey have expanded Saxenda coverage considerably since 2020. Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, covers Saxenda on its formulary with prior authorization for most employer-sponsored plans. Aetna, Cigna, and UnitedHealthcare plans sold in the NJ marketplace also list Saxenda, though tier placement varies.

Tier placement determines co-pay. On a preferred brand tier (Tier 2), co-pays typically range from $40 to $75 per month. On a non-preferred or specialty tier (Tier 3 or 4), co-pays can climb to $100 to $250, or plans may apply coinsurance of 20 to 40 percent. A patient on a Tier 4 specialty plan paying 30% coinsurance on $1,349 would owe roughly $405 per fill before any savings card.

Not every plan covers weight management medications. Self-funded employer plans are not subject to New Jersey's state insurance mandates and may explicitly exclude anti-obesity drugs from their formulary. The quickest way to check: call the number on the back of the insurance card and ask whether Saxenda (NDC 0169-4060-12) is covered under the pharmacy benefit.

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity recommended that clinicians offer FDA-approved anti-obesity medications to patients with BMI ≥30, or ≥27 with comorbidities, who have not achieved target weight loss with lifestyle modification alone [4]. This recommendation has been cited in coverage policy updates by several New Jersey insurers as part of their medical necessity criteria.

The Novo Nordisk Savings Card in New Jersey

Novo Nordisk offers a manufacturer savings card for Saxenda that can reduce the monthly out-of-pocket cost to as low as $25 for commercially insured patients. The card is valid at all New Jersey pharmacies that accept manufacturer co-pay cards.

Eligibility rules are straightforward. Patients must have commercial insurance that covers Saxenda (even with a high co-pay). Medicare, Medicaid, TRICARE, and other government-funded insurance beneficiaries are not eligible. The savings card covers up to a set dollar amount per fill, and the annual maximum benefit varies by program year. In recent program years, the cap has typically been around $200 per fill.

Here is how it works in practice: a patient fills Saxenda at a CVS in Newark. Insurance processes the claim and determines a $150 co-pay. The savings card applies at the point of sale, reducing the patient's share to $25. Novo Nordisk absorbs the $125 difference. If the co-pay exceeds the card's per-fill maximum, the patient pays the overage.

Patients can enroll online at the Novo Nordisk patient assistance website or receive a card through their prescriber's office. The card must be presented to the pharmacist at each fill. It cannot be retroactively applied to fills already processed.

Compounded Liraglutide 3 mg in New Jersey

Compounded liraglutide 3 mg is available in New Jersey through licensed 503A compounding pharmacies. A 503A pharmacy compounds medications pursuant to individual patient prescriptions, operating under state board of pharmacy oversight. New Jersey's Board of Pharmacy licenses and inspects these facilities.

Compounded liraglutide offers a potential cost advantage. While the brand Saxenda lists at $1,349 per month, compounded versions from 503A pharmacies have been priced significantly lower, with some NJ-accessible compounders offering 30-day supplies in the range of $300 to $500 depending on the pharmacy and dosing configuration.

There are trade-offs. Compounded drugs are not FDA-approved products. They do not undergo the same batch-by-batch release testing that Novo Nordisk applies to every lot of Saxenda. The FDA's guidance on pharmacy compounding outlines the distinction: compounded medications are appropriate when a patient has a medical need that cannot be met by an FDA-approved product, such as an allergy to an inactive ingredient or a need for a different dosage form [5].

The American Association of Clinical Endocrinology (AACE) has noted that compounded GLP-1 receptor agonists may not be bioequivalent to their brand counterparts. Patients considering compounded liraglutide should discuss potency verification and sterility testing with their prescriber. A reputable 503A pharmacy will provide a certificate of analysis for each batch.

New Jersey law permits prescribers to write prescriptions for compounded medications when clinically appropriate. The prescription must specify the compounded drug, and the pharmacy must hold a valid NJ compounding license. Patients receiving compounded liraglutide via out-of-state pharmacies should confirm the pharmacy is licensed to ship into New Jersey.

Saxenda via Telehealth in New Jersey

Telehealth prescribing of Saxenda is legal in New Jersey. The state's telehealth parity law (P.L. 2017, c.117) requires insurers to cover telehealth visits at parity with in-person visits, and prescribers licensed in New Jersey can establish a patient-prescriber relationship via audio-visual communication.

This means a New Jersey resident can consult with a licensed physician, nurse practitioner, or physician assistant through a telehealth platform, receive a Saxenda prescription, and have it sent to any NJ pharmacy. Several national telehealth platforms specializing in weight management operate in the state.

Telehealth visits for weight management typically cost $50 to $150 for an initial consultation and $30 to $75 for follow-ups when paying out of pocket. With insurance, the visit co-pay matches in-person specialist visits.

One practical advantage of telehealth: faster prior authorization turnaround. Many telehealth platforms have integrated prior authorization workflows that submit to the insurer electronically at the time of the visit. This can shorten the approval window from days to hours in some cases.

The SCALE Maintenance trial, a follow-on study published in the International Journal of Obesity, showed that patients who continued liraglutide 3 mg after initial weight loss maintained significantly more weight loss than those switched to placebo, with a treatment difference of 6.2% at week 56 [6]. Continued prescriber contact, whether in-person or via telehealth, supports the ongoing monitoring that liraglutide therapy requires, including assessment of gastrointestinal side effects and dose adherence.

How to Find the Lowest Saxenda Price in New Jersey

A systematic approach to reducing Saxenda costs in New Jersey involves stacking multiple savings mechanisms. Start with insurance verification. If the plan covers Saxenda, apply the Novo Nordisk savings card on top. This combination can drop monthly costs to $25 for many patients.

If insurance does not cover Saxenda or the patient is uninsured, the next step is to evaluate compounded liraglutide 3 mg from a licensed 503A pharmacy. Savings of 60 to 75 percent versus brand Saxenda are common, though patients should verify the pharmacy's accreditation and compounding practices.

Novo Nordisk also operates a patient assistance program (PAP) for uninsured patients who meet income criteria (generally at or below 400% of the federal poverty level). Approved applicants receive Saxenda at no cost. The application requires income documentation and a prescriber signature.

GoodRx, RxSaver, and similar discount platforms aggregate pharmacy pricing in real time. Checking these aggregators for New Jersey ZIP codes can reveal price variation of 5 to 10 percent across pharmacies within the same metro area. The lowest price is not always at the nearest pharmacy.

The 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults recommended that clinicians consider FDA-approved pharmacotherapy as an adjunct to lifestyle intervention for patients who do not reach target weight loss goals [7]. Aligning a cost-reduction strategy with a structured treatment plan increases the likelihood that a patient can sustain therapy long enough to reach clinically meaningful weight loss, which the SCALE trial defined as 5% or greater of baseline body weight [2].

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "The biggest barrier to anti-obesity pharmacotherapy is not efficacy. It is access and affordability. When patients cannot sustain medication costs month to month, they discontinue treatment and regain weight" [8].

Saxenda vs. Newer GLP-1 Options: Cost Context for NJ Patients

Saxenda's pricing in New Jersey exists within a broader GLP-1 receptor agonist market. Wegovy (semaglutide 2.4 mg), approved in 2021, lists at approximately $1,349 per month as well, but is dosed weekly rather than daily. Zepbound (tirzepatide), a dual GIP/GLP-1 agonist, lists at roughly $1,059 per month.

The STEP 1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [9]. By comparison, the SCALE trial showed 8.0% with liraglutide 3 mg at 56 weeks [2]. The greater efficacy of newer agents has shifted some prescriber and payer preference away from Saxenda, which can paradoxically improve Saxenda access: some insurers now place Saxenda on a lower (less restrictive) formulary tier.

For New Jersey patients weighing Saxenda against alternatives, the decision should factor in insurance formulary placement, co-pay after savings card, injection frequency preference (daily vs. weekly), and individual response. A patient who tolerates liraglutide well and has favorable insurance coverage may find Saxenda the most cost-effective option despite its older clinical profile.

Side Effects and Monitoring Costs to Factor In

Saxenda's most common side effects are gastrointestinal: nausea (39.3%), diarrhea (20.9%), constipation (19.4%), and vomiting (15.7%) according to the FDA label [1]. These effects are most pronounced during dose escalation and typically diminish over 4 to 8 weeks.

Monitoring costs add to the total expense of therapy. The FDA recommends checking heart rate periodically (liraglutide increases resting heart rate by an average of 2.0 beats per minute), monitoring for signs of pancreatitis, and assessing renal function in patients with pre-existing kidney disease. Standard lab work (comprehensive metabolic panel, lipid panel, hemoglobin A1c) every 3 to 6 months is consistent with the AACE/ACE obesity management guidelines [10]. In New Jersey, these labs typically cost $20 to $50 with insurance or $100 to $200 at cash-pay rates.

Patients should discontinue Saxenda if they have not achieved at least 4% weight loss after 16 weeks at the full 3 mg dose, per the FDA label [1]. Continuing beyond this point in non-responders exposes patients to side effects and costs without proportional benefit.